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Home Blood Glucose Monitoring in
Type 2 Diabetes
Broken health care system undermines study’s impact
T
he Diabetes Control and Complica-
tions Trial (DCCT) (1) would not
havebeenpossiblewithouttheadvent
of several technologies, including self-
monitoring of blood glucose (SMBG). Af-
tertheresultsofthatlandmarkstudywere
reported in 1993, SMBG was considered
the standard of care for type 1 diabetic
patients. The same was true for insulin-
requiringtype2 diabetic patients after the
report of the UK Prospective Diabetes
Study (UKPDS) in 1998 (2). However,
cost pressures have now caused some to
questionSMBGintype1diabetes(3),and
we continue to struggle with conﬂicting
evidence for those patients with type 2
diabetes not receiving insulin. The funda-
mentalproblemhasbeendifﬁcultyintrial
design with many of the challenges carry-
ing over from clinical trials to clinical
practice.
For example, is the patient with type 2
diabetes even willing and able to perform
SMBG? And, based on the glucose data, is
the patient engaged enough to make be-
havioral changes that would improve
glucose control? And even for those indi-
viduals who are able to make signiﬁcant
lifestyle changes, will they be willing to
initiate insulin therapy if indicated? From
the provider’s perspective, is there time to
review the data and potentially intensify
therapywiththatinformation?Canthepro-
vider even easily access the data, especially
if there is a large amount of information in
the 2 or 3 weeks before a clinic appoint-
ment? If the clinician cannot download
the data, will the patient be willing to share
theinformationeitherwithapaperlogbook
or perhaps a computerized tool such as a
spreadsheet or even a smart-phone app?
What becomes clear is that for data to be
exchanged successfully, both the patient
and the provider (including in a clinical
trial) need to appreciate that exchange.
Another very practical question for
SMBG among type 2 diabetic patients is
what is its ideal frequency for a patient on
metformin, with or without a sulfonyl-
urea or glucagon-like peptide 1 agonist?
For Medicare beneﬁciaries, patients not
receiving insulin are allowed 100 test
strips every 3 months (4). For these 100
strips, would it be best to test daily (at
the same time or at different times of the
day?) or to cluster the testing over a few
days during this 3-month period?
The answers to some of these ques-
tions are addressed by Polonsky et al. in
this issue of Diabetes Care (5). In this
12-month trial performed in 34 primary
care practices, 483 type 2 diabetic pa-
tients (mean A1C 5 8.9%) were random-
ized either to an active control group
(ACG) where patients were instructed to
use their meter based on their physicians’
recommendations (but no additional
prompting, training, or instruction) or
to a structured testing group (STG) where
subjects used a paper tool to help analyze
SMBG results and patterns. Subjects in the
STG were asked to record/plot a 7-point
SMBG proﬁle on 3 consecutive days prior
toeachofthe5clinicvisitsscheduledinthe
12-month period. Importantly, these par-
ticipants were also taught how to identify
glycemic patterns and how to best address
problemswith changesinphysicalactivity,
portion sizes, and/or meal composition.
These completed forms were reviewed at
each clinic visit and, accordingly, patients
were instructed on how to make further
adjustments in their lifestyle and medica-
tion changes were made.
The results were not surprising.
Intention-to-treat analysis resulted in an
A1C changefavoring the STG participants
by 20.3% (P 5 0.04), while the per-
protocol analysis showed an even greater
reduction by 20.5% (P , 0.003). This
difference is noteworthy in that it takes
into account how well the participants
complied with the protocol—a fact not
necessarily appreciated when only report-
ing the intention-to-treat results. No mat-
ter the population studied (in this report,
over half the population did not have
any college education)—and even if the
providersareengagedandtheSMBGtech-
nology and the ability for analysis are
ideal—patient behavior and desire for im-
proved diabetes control are required.
Also not surprising is that structured,
intensive SMBG performed in the STG
compared with random testing in the
ACG resulted in more treatment change
recommendations, most notably at the
1-month visit. In the STG, almost twice
as many subjects started insulin therapy,
though the authors note that this alone
wasnotresponsibleforthegroup’soverall
improvement. It is important to appreci-
ate that the overall frequency of SMBG
was lower in the STG, further emphasiz-
ingthatstructured,intensiveSMBGwhen
performed at key predetermined times
can be an effective strategy. Averaging
less than one test daily, the per-protocol
STG had a twelve-month mean A1C of
7.6%. While not ideal, control was im-
proved, hypoglycemia was not increased,
and resources used (in terms of strip use)
wereminimalandnotgreaterthanwhatis
currently allowed by Medicare for indi-
viduals not receiving insulin therapy.
That the ACG had a 0.9% reduction in
A1Cattheendofthestudycomparedwith
baseline is noteworthy. This points to how
additional attention (including free meters,
strips, and additional clinic visits) to di-
abetes management can directly inﬂuence
overall control. Further attention on top of
this as seen in the STG resulted in addi-
tional reduction in A1C. The good news
is that this supports a fundamental fact we
all should appreciate: many patients can
achieve reasonable diabetes control in a
primary care setting without a dazzling
array of sophisticated technology. The
recipe for success would include a well-
intentioned and motivated patient, an in-
terested and engaged clinician, the usually
available agents to treat type 2 diabetes
(including basal insulin), glucose testing to
beperformedonlyatspeciﬁctimestoallow
for pattern recognition, and at the very
least a paper tool to allow both physician
and patient to understand where changes
needtobemade.Ifanyoneofthesefactors
is not present, success (as we have seen so
many times) will be unlikely.
What else can we conclude? First,
these results do not apply to patients who
require more sophisticated diabetes regi-
mens, including prandial insulin, where
more frequent SMBG will be necessary to
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to minimize hypoglycemia.
Furthermore, it also seems to me that
while we have spent so much time,
energy, and money examining the impact
of SMBG on the management of type 2
diabetes, the more important problem is
determining how we can better improve
our systems of care so that the time spent
by the primary care physicians in this
study is the norm and not a contrived
component of a study protocol. This is a
fundamental problem with most of the
studies assessing the impact of SMBG in
the management of type 2 diabetes: the
study protocols do not necessarily
replicate a real-life practice setting. In
this era of “clinical efﬁciency” and “in-
creased productivity,” the signiﬁcance of
much of this type of research is reduced.
While the article by Polonsky et al. is
an important contribution to the litera-
ture, we have to be realistic that many if
not most primary care physicians do not
havethetimeorinfrastructuretoreplicate
these ﬁndings (6). While one could argue
thattimewiththeproviderisasimportant
as the glucose test strips themselves, fu-
ture research should focus on how to bet-
ter achieve improved glycemic outcomes
with less clinician intervention. Potential
solutions would begin with better use of
web-based or smart-phone technology
for patient instruction and management.
Additional strategies would include
more group visits, less physician and
greater nonphysician interaction, and
somedegreeofpeer-to-peerinvolvement,
all in addition to a strategy of care similar
to the STG in the current study. Our fu-
ture clinical trials will need to better rep-
licate our current system of care. Until
then, the controversy regarding SMBG
in type 2 diabetes will not be resolved.
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